Molecular diagnosis of multiple endocrine neoplasia type 2A

South African Medical Journal

Volumn 88, Issue 1, 1998, Pages 39-42

  Pegoraro, R J ^a   Hacking, D J ^b   Buck, R H ^c   Rom, L ^a   Lanning, P A ^a   Berger, G M B ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Durban Oncology Centre   (South Africa)

^c Drs Bouwer Pillay Morris and Partners

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; CATECHOLAMINE;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; DNA DETERMINATION; FAMILY STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; MALE; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEOTIDE SEQUENCE; PEDIGREE; PHEOCHROMOCYTOMA; PROTO ONCOGENE; RESTRICTION MAPPING; RISK ASSESSMENT; SCHOOL CHILD; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADULT; CALCITONIN; CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PEDIGREE; PENTAGASTRIN; SEQUENCE ANALYSIS, DNA;

EID: 0031912119     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Easton DF, Ponder BA, Cummings T, et al. The clinical and screening age-at-onset distribution for the MEN 2A syndrome. Am J Hum Genet 1989; 44: 208-215.
2. Mathew CGP, Chin KS, Easton DF, et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987; 328: 527-528.
3. Simpson NE, Kidd KK, Goodfellow PJ, et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 1987; 328: 528-530.
4. Sobol H, Narod SA, Nakamura Y, et al. Screening for multiple endocrine neoplasia type 2A with DNA-polymorphism analysis. N Engl J Med 1989; 321: 996-1001.
5. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994; 91: 1579-1583.
6. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994; 6: 70-74.
7. Donis-Keller H, Dou S, Chi D, et al. Mutations with RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-856.
8. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993; 63: 458-460.
9. Muligan LM, Marsh DJ, Robinson BG, et al. for the International RET Mutation Consortium. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995; 238: 343-346.
10. Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994; 220: 237-247.
11. Chan DW, Sell S. Tumor markers. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia: WB Saunders. 1994: 897-927.
12. Odink J, Sandman H, Schreurs WH. Determination of free and total catecholamines and salsoinol in urine by ion-pair re versed-phase liquid chromatography with electrochemical detection after a one-step sample clean-up. J Chromatogr 1986; 377: 145-154.
13. Graham PE, Smythe GA, Edwards GA. Laboratory diagnosis of phaeochromocytoma: which analytes should we measure? Ann Clin Biochem 1993; 30: 129-134.
14. Feldman GL, Kambouris M, Talpos GB, Mulligan LM, Ponder BA, Jackson CE. Clinical value of direct DNA analysis of the RET proto-oncogene in families with multiple endocrine neoplasia type 2A. Surgery 1994; 116: 1042-1047.
15. Hoppener JWM, Lips CJM. RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects. Eur J Clin Invest 1996; 26: 613-624.
16. National Advisory Council for Human Genome Research. Statement on the use of DNA testing for presymptomatic identification of cancer risk. JAMA 1994; 271: 785.
17. Gagel RF, Cote GJ, Martins Bugalho MJ, et al. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med 1995; 238: 333-341.
18. Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 1996 335: 943-951.
19. Cote GJ, Wohlk N, Evans D, Goepfert H, Gagel RF. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Baillieres Clin Endocrinol Metab 1995; 9: 609-630.
20. Hopley M, Huddle KRL. Multiple endocrine neoplasia type 2A in a black South African family. S Afr Med J 1997; 87: 371-372.